2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle  
04/16/18Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
FDA Confirms Vitaros Regulatory Pathway  Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of its end-of-review meeting with the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Vitaros™ (alprostadil, DDAIP.HCl), a top... 
 Printer Friendly Version
04/04/18Apricus Biosciences Announces Closing of $3.55 Million Public Offering
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the closing of its previously announced public offering of an aggregate of approximately 7.1 million shares of common stock at a price to the public of $0.50 per share. Investors also received warrants to purchase up to an aggregate of approximately 3.55 million shares of common stock with an exercise pric... 
 Printer Friendly Version
03/28/18Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has priced a public offering of an aggregate of approximately 7.1 million shares of common stock at a price to the public of $0.50 per share. Investors will also receive warrants to purchase up to an aggregate of approximately 3.55 million shares of common stock with an exercise price of $0.50 per ... 
 Printer Friendly Version
03/27/18Apricus Biosciences Announces Proposed Public Offering
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a public offering of shares of common stock and warrants to purchase shares of common stock. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The Company intends to use the net proceeds from the offering for working capital and general corporate p... 
 Printer Friendly Version
03/26/18Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA
Meeting Scheduled for April 12, 2018 SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its end-of-review meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the New Drug Application (“NDA”) for Vitaros™ (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction, is now scheduled to be held on April 12, 2018... 
 Printer Friendly Version
03/01/18Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
Company Expects to Submit Vitaros End of Review Meeting Request This Month Vitaros End-of-Review Meeting Expected to Occur in April 2018 Company Expects Cash Runway Through 2018 Conference Call / Webcast Today, March 1, 2018 at 4:30 p.m. ET SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the fourth quarter of 2017 and provide... 
 Printer Friendly Version
02/21/18Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2017 financial results will be released on Thursday, March 1, 2018 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Thursday, March 1, 2018, at 4:30 p.m. Eastern Time to discuss the financial results and its plans for addressing th... 
 Printer Friendly Version
02/16/18Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the New Drug Application (“NDA”) of Vitaros™ (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction.  The CRL indic... 
 Printer Friendly Version